CAMP NASDAQ
CAMP4 Therapeutics Corporation
1W: +2.0%
1M: +5.3%
3M: -6.5%
YTD: -33.3%
1Y: +35.6%
$4.00
+0.16 (+4.17%)
Weekly Expected Move ±8.9%
$3
$4
$4
$4
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
6 relationships4
As Filer
counterparties named
2
As Counterparty
mentioned by others
1
Rel. Types
2021-07-12
Earliest Filing
2025-12-23
Latest Filing
partner: 4
Counterparties (Filed by CAMP)
4 relationshipsCompanies named in CAMP's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| ARE-MA Region No. 59, LLC | — | partner | Landlord entering lease amendment and affiliate of new landlord | 2025-12-23 | View |
| ARE-MA Region No. 75, LLC | — | partner | Landlord entering new lease agreement | 2025-12-23 | View |
| GlaxoSmithKline Intellectual Property (No. 3) Limited | — | partner | Entered into a Research, Collaboration and License Agreement for ASO therapeutics targeting neurodegenerative and kidney | 2025-12-18 | View |
| Leerink Partners LLC | — | partner | Underwriter for the offering of 5,000,000 shares of common stock | 2025-12-18 | View |
Mentioned As Counterparty
2 mentionsOther companies that named CAMP in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| FULC Fulcrum Therapeutics, Inc. | partner | Fulcrum received a worldwide exclusive license from CAMP4 for Diamond Blackfan Anemia program rights. | 2023-07-10 | View |
| OPK OPKO HEALTH, INC. | licensee | OPKO granted an exclusive license for AntagoNAT technology to CAMP4 in exchange for upfront payment, preferred stock, an | 2021-07-12 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-28 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-13 | Earnings Release; Exhibits | View | |
| 2026-08-04 | Material Agreement; Unregistered Equity Sales; Regulation FD; Exhibits | Agreement | View |
| 2026-07-27 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-12 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-14 | Regulation FD; Exhibits | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-03-24 | Officer/Director Change | View | |
| 2026-03-05 | Completion of Acquisition or Disposition of Assets; Regulation FD Disclosure; Financial Statements a | Acquisition | View |
| 2026-01-09 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-12-23 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement | Agreement | View |
| 2025-12-18 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-12-18 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-01 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-09-10 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Departure/Electio | Agreement | View |
| 2025-08-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-13 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-16 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-05-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR